A new prostate cancer diagnosis is overwhelming. Most prostate cancers are highly treatable, and the right approach depends on your tumor, your health, and your priorities. Dr. Weiner offers the full range of evidence-based options at Cedars-Sinai, with care tailored to you.
We respond within one business day.
Cedars-Sinai Medical Center · 8635 W 3rd St, Suite 1070W, Los Angeles, CA 90048
Clinical questions: GroupAskDrWeiner@cshs.org
Most prostate cancer is highly treatable. Take a breath. Here is what to do in your first week:
A free tool Dr. Weiner uses to help you organize your questions and records before the visit. Ten minutes here makes the visit work harder for you.
Reviews shared by patients on Google and Yelp.
"I was diagnosed with an aggressive form of prostate cancer and had to choose a surgeon. Dr. Weiner was my choice. He does a robotic nerve-sparing procedure that resulted in a very good outcome. I am very happy with his professionalism and talent."Verified patient review · Robotic prostatectomy
"Dr. Weiner was informative, confident, patient and never condescending. He provided a sense of comfort and security before, during and after the procedure."Verified patient review
"By far the best and most caring doctor. With most doctors you would be fortunate if they return your call after a week. Dr. Weiner would call and check up on me constantly making sure my recovery was on track."Verified patient review · Robotic prostatectomy
"Dr. Weiner provided exceptional care from beginning to end. He took the time to explain procedures and aftercare, and follow-ups were constant. I feel confident my life has been extended thanks to him and the Cedars team."Verified patient review
The plan is built around your tumor biology, your goals, and the best evidence available today.
Structured monitoring with PSA, MRI, and biopsy can safely defer treatment for many men with low-risk disease, sometimes indefinitely.
Minimally invasive removal of the prostate using the da Vinci platform, with nerve-sparing whenever oncologically safe.
For select men with single-focus, intermediate-risk disease. Dr. Weiner has published peer-reviewed research on the genomic biomarkers that help identify candidates.
External beam and brachytherapy are excellent options for many patients. We partner with Cedars-Sinai radiation oncology so you can compare side by side.
High-risk and locally advanced cancer often does best with surgery or radiation combined with hormonal therapy and clinical-trial access.
Salvage surgery, PSMA PET imaging, genetic testing, and clinical-trial access for biochemical recurrence, oligometastatic, and castration-resistant disease.
Consultations are 45 to 60 minutes. We review your imaging, pathology, and prior testing together and walk through every reasonable option side by side. Second opinions are welcome; you do not have to transfer care.
Before the visit, our team gathers your records and confirms your insurance. After the visit, you receive a written summary of the discussion and the recommended next steps.
Three trials currently enrolling. If one looks relevant, mention it at your consultation or contact the study team directly.
For: Patients on active surveillance with a biopsy in the next 3 to 6 months.
Phase 2 study testing whether a cholesterol-lowering medication (typically Vytorin) helps CD8+ T cells move into prostate tumors. Adds the medication, blood work, and questionnaires to the standard-of-care biopsy you already had planned.
PI: Hyung Kim, MD · Cedars-Sinai, Beverly Hills
For: Patients with Gleason 7+ prostate cancer planning a radical prostatectomy.
Phase 2 study of two ounces of walnuts daily in the weeks before surgery. Compares biopsy and surgical tissue to measure changes in cancer cell growth. Does not change surgery timing or type.
PI: Stephen Freedland, MD · NCT: NCT03824652
Ana Martin · ana.martin@cshs.org
For: Patients planning a radical prostatectomy at Cedars-Sinai.
Phase 2/3 study of an IV dye (ZW800-1) that makes ureters glow under near-infrared camera, helping surgeons see and avoid them. All participants receive the active medication.
NCT: NCT06101745 · Cedars-Sinai
Final eligibility is determined by the study team after a brief screening conversation. General inquiries: clinicaltrials@cshs.org.
Often, no. Many low-risk prostate cancers are best managed with active surveillance, where we monitor the cancer over time with PSA, MRI, and periodic biopsy. Treatment is added only if there is meaningful evidence of progression.
This is an individual discussion. Recovery of urinary continence and erectile function depends on your age, your baseline function, your tumor's location, and how much of the nerve tissue can be preserved. We talk through realistic expectations for your specific case before any decision is made.
Both are excellent options for localized prostate cancer with similar long-term cancer control in many cases. The right choice depends on your tumor characteristics, your other health conditions, and how you weigh the side-effect profiles. Dr. Weiner partners with radiation oncology so you can hear both sides honestly.
Plans accepted include Aetna, Aetna HMO, Anthem Blue Cross, Blue Cross Blue Shield, Blue Cross of California HMO, Blue Shield of California, Blue Shield of California HMO, Cigna, Humana, Humana HMO, Kaiser Permanente, Medicare, UnitedHealthcare, and UnitedHealthcare HMO. Our team will verify your benefits before your visit.
Yes. Many of our patients come for a second opinion only. We provide a written summary of our recommendations that you can take back to your local team if you choose to stay with them.
Yes. Telehealth visits are available for established patients in California and for select consultations. Some pre-operative and post-operative visits can also be done virtually.
Cedars-Sinai is an active research center, and Dr. Weiner's lab partners with the broader prostate cancer trial portfolio. If a trial is a fit for your situation, we will discuss it openly.
The first conversation is the hardest. Once you have a plan, everything gets easier.